* Note: Prices are in Million (M) USD.
Description:
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $1,955 M
Debt : $0 M
EBITDA : $1,308 M
Since Cash is greater than Total Debt, 5 points assigned.
This criteria used industry in which company operates:
Sector: Healthcare
Industry: Biotechnology
Based on industry, 5 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Forward PE Ratio: 13.87
Since Forward PE Ratio is less than 15, 5 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Using last 20 overlapping fiscal years (max 20).Average Free Cash Flow: $112 M
Average Revenue: $1,297 M
Revenue Converted To Free Cash Flow (%): 8.6%
Since Free Cash Flow (FCF) to Revenue percentage is less than 15, 1 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $4,241 M
Revenue 4 Years Ago (2020-12-31): $2,667 M
Last 5 Years Average Revenue Growth: 12%
Since Revenue Growth is between 10 - 15, 3 points assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $211 M
Share Count 5 Years Ago (2020-12-31): $218 M
Company is buying back its own shares, 3 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $6.35
Trailing 12-Month Earnings Per Share (EPS): $5.85
Average Earnings Per Share (EPS): $6.10
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0%
Since Dividend Per Share is less than or equal to 0, 0 point assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Using last 10 valid ROE years (max 20).Average ROE: 6.6%
Since Average ROE is less than 10, 1 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $85
52-Week Low: $54
Threshold Price (15% Above 52-Week Low): $62
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $15,308 M
Since Market Cap is between 10B - 100B, 2 points assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 3% exposure of Total Portfolio.
Value-Trade has assigned 25 points to above Incyte Corporation (INCY) stock.
Last 4 Years Avg PE 26.04, Fair Value PE 25, Industry Based PE 20, Growth Based PE 11, RCFC Based PE 18.9, ROE Based PE 15.31, Risk-Free Anchored PE (25% MoS) 17.08. Based on these 7 values, average assigned is 19.05. Value-Trades has assined P/E value 19.05. Since an average (Current Year EPS + Next Year EPS) earning per share is $6.1.
The fair value of Incyte Corporation (INCY) stock should be (19.05 x $6.1) = $116.19.
